Gun Control Lies that Democrats Will Tell in the Days

New Post Public Reply Private Reply Replies (0) Message Board
PoemStone
208
Gun Control Lies that Democrats Will Tell in the Days Ahead
< >

gunshow-640x480.jpg

#1. Unlike other countries, America is plagued by mass shootings.

The Left claims that because the possession of guns in America is greater than in other countries, that causes the incidence of mass shootings to be higher too. However, that claim is based on a false premise. While the first statement is true, the second statement is false.

No-one has studied this issue more thoroughly than economist and author John Lott Jr. His study of mass shootings around the world revealed some interesting statistics. America has 4.6 percent of the world’s population. But America has only 1.49 percent of the murders worldwide, and less than 1.15 percent of the mass public shooters. America ranks 64th out of 97 countries in mass shootings per capita—a long way behind countries where the possession of firearms is uncommon.

#2. Background checks stop mass shootings.

This lie is particularly misleading in the wake of the El Paso and Dayton mass shootings. Both shooters purchased their firearms legally from dealers who were Federal Firearms Licensees (FFL), and both passed the background checks. Therefore, existing background checks did nothing to stop the shootings, and universal background checks (compelled by H.R. 8, which passed the Democrat-controlled House in February) certainly would not have changed anything. Meanwhile law-abiding citizens would find it difficult to lend or sell firearms to family and friends.

Although background checks are necessary and do serve a legitimate purpose, as I have written previously, the biggest problem with the whole background check system is that it is routinely circumvented by criminals. Instead of buying the gun himself, the criminal simply has a person with a clean record buy the gun for him. These “straw purchaser” arrangements are illegal, but they’re almost impossible to detect and extremely difficult to prosecute. Indeed, it appears that the 2015 San Bernardino mass shooter acquired his firearms that way.

#3. Gun-free zones work.

Whenever a mass shooting occurs, Democrats typically push for laws forbidding guns in locations like that where the shooting took place. They evidently believe that a plastic sign on the door saying that no guns are allowed will stop potential shooters. It’s a fantasy. Worse, it serves as an invitation to criminals. One might as well post a sign saying “defenseless victims inside.”

The empirical data show just how dangerous gun free zones are. As pointed out by John Lott Jr., fully 98 percent of mass public shootings since 1950 occurred in places where citizens are banned from having guns. Most shooters recognize that they will encounter less resistance if their intended victims are unarmed. Or stated differently, the only thing that stops a bad guy with a gun is a good guy with a gun; and the criminals know it.

#4. AR-style rifles are preferred by mass shooters.

The Left loves to hate AR-style rifles, better described as “modern rifles.” Their collapsible stocks, detachable magazines and general cosmetic features cause gun control advocates to hyperventilate. These firearms look like military rifles, therefore they must be bad; or so the Left believes. Hence the Left’s constant demand to institute another “assault weapons ban.”

However, it turns out that the overwhelming majority of mass shooters don’t actually use AR-style rifles. The Congressional Research Service wrote a lengthy report on this subject in 2015, defining a mass shooting as one in which three or more people are killed in a single incident. The study found that out of 317 mass shootings between 1999 and 2013, offenders used AR-style rifles in 31 incidents – or only 9.78% of the time.

This shouldn’t be particularly surprising. AR-style rifles are difficult to conceal, and semiautomatic pistols can deliver just as many bullets just as quickly. That’s why AR-style rifles aren’t usually used by most mass shooters, or by other criminals either. The notion that banning this type of firearm would put a dent in mass shootings is nonsense.

#5. So-called “smart guns” are the answer.

Perhaps the most idiotic pro-gun-control lie was delivered by Joe Biden at a campaign event in June. He said: “If I get elected president of the United States of America with your help, if that happens, guns, we have the capacity now in a James Bond-style to make sure no one can pull a trigger unless their DNA and fingerprint is on it. We have that capacity to do it now.” He repeated a similar claim during the second night of the first Democratic presidential debates.

Biden has no idea what he’s talking about. There is no such thing as a gun that can perform a DNA match. DNA matching is a time-consuming process that involves highly specialized equipment. With regard to fingerprints, at least one company is trying to develop a gun that can recognize a fingerprint, but it’s in the early development stage—and it has encountered all sorts of problems. There are no “smart guns” like Biden described currently on the market.

The closest thing to a smart gun that exists is a pistol that requires a matching bracelet in the vicinity for the gun to operate. However, that gun is easily defeated by about $15 worth of magnets; and it costs $1,800 – about four times the price of an equivalent pistol. If ever the fingerprint technology makes it to market, it will undoubtedly be even more expensive. And that’s the problem with any law requiring gun dealers to sell only smart guns if the technology becomes viable someday. The average gun buyer won’t be able to afford them.

But that’s exactly what the Left wants to see happen. If the Second Amendment forbids them from disarming all Americans, then they’d love to see firearms and ammunition become too expensive for most people to buy.

These are the lies that will be told in the U.S. Senate in the coming weeks—both by Democrats and by moderate Republicans. Let’s hope that the rest of the Senators do their homework and rebut such lies with the truth.
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 202

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 199

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 166

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
Clarins Dazzles Austin with Skin Longevity Event

Updated Category News Views 42

Clarins Takes Austin by Storm Under the vast Austin sky, something remarkable unfolded as Clarins transformed the scene with a flashy rooftop affair that screamed innovation and elegance. They weren’t just showing off fancy bottles of beauty potion; they were stirring the pot, merging science with a splash of high-end glitz. This wasn’t just another product pitch—it...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 249

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 309

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 186

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
BAIC FOTON Eyes African Market with Strategic Moves

Updated Category News Views 84

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 393

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

Updated Category News Views 92

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Continue Reading

Top 5 Most Recently Viewed Articles

Farmmi Receives Extension to Comply with NASDAQ Requirements

Updated Category News Views 64

Farmmi Secures NASDAQ Compliance Extension Farmmi, Inc. (NASDAQ: FAMI), a supplier of agricultural products, has been granted a 180-day extension by NASDAQ to meet its crucial minimum bid price requirement. This extension allows the company until the spring of 2025 to elevate its ordinary share bid price to at least $1.00 for at least ten consecutive business days. The...

Continue Reading
The Neurotechnology Surge: $57B Market by 2034

Updated Category News Views 16

Neurotechnology: The Rising Giant Elbows on the table, let's chew the fat about neurotechnology. The market, dizzyingly projected to soar past USD 57 billion by 2034, is on an explosive trajectory. Folk wiser than us predict an annual growth rate hanging around 14%. This ain't just whispers in coffee shops; it's cold, hard data from DelveInsight’s Market Insights...

Continue Reading
Reviva Pharmaceuticals' New Phase 3 Study for Schizophrenia Drug

Updated Category News Views 99

Reviva Pharmaceuticals' Regulatory Update Reviva Pharmaceuticals Holdings Inc. (NASDAQ: RVPH) has recently provided an update regarding their journey with brilaroxazine, a novel drug aimed at treating schizophrenia. This news comes after a pre-New Drug Application meeting with the U.S. Food and Drug Administration (FDA). About Brilaroxazine Brilaroxazine is an innovative...

Continue Reading
Lowe's Reports Strong Earnings Amid Strategic Acquisitions

Updated Category News Views 117

Strong Q2 Earnings Surprise Lowe’s Companies Inc (NYSE: LOW) experienced better-than-expected second quarter earnings, bringing a burst of optimism for investors. The home improvement giant saw its stock increase by approximately 2% shortly after announcing its Q2 financial results. Having recorded solid performance through the quarter, Lowe’s exceeded analysts'...

Continue Reading
Invideo and Kling AI Unite for Game-Changing Visuals

Updated Category News Views 153

Invideo and Kling AI Collaborate to Redefine Video Editing Invideo has recently partnered with Kling AI to introduce an exciting tool known as VFX House. This innovative feature empowers creators with studio-level control for their video projects, offering enhanced capabilities for both marketing and editorial work. Unlocking New Possibilities with VFX House The...

Continue Reading